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Introduction
Pre-B cell acute lymphoblastic leukemia (pre-B ALL) is the most 
prevalent leukemia in children. The most common chromosomal 
abnormalities associated with pre-B ALL are t(12;21), resulting 
in the ETV6-RUNX1 fusion gene, and hyperdiploidy (>50 chro-
mosomes). A substantial proportion of cases have an apparently 
cytogenetically normal karyotype.1 Evidence suggests that the 
ETV6-RUNX1 fusion gene can arise in utero2 but is insufficient 
in isolation to cause malignancy.3 Cooperating mutations are 
likely required for progression to leukemia and mutation and copy 
number aberration in genes involved in B-lymphoid development, 
including PAX5, IKZF1 and TCF3, are present in up to 40% of 
ETV6-RUNX1 cases.4 As these events do not account for all cases, 
we hypothesized that epigenetic dysregulation may constitute 
an additional oncogenic hit leading to leukemogenesis. Previous 
studies have described aberrant promoter DNA methylation of 
tumor suppressor genes including E-cadherin, DKK and p16 in 
childhood pre-B ALL.5 To date, there has been little consensus 
concerning locus-specific DNA methylation in childhood ALL 
due to the range of methods used to measure DNA methylation 
on disparate combinations of distinct subgroups of ALL.6
pre-B cell acute lymphoblastic leukemia (ALL) is the most prevalent childhood malignancy and remains one of the highest 
causes of childhood mortality. Despite this, the mechanisms leading to disease remain poorly understood. We asked if 
recurrent aberrant DNA methylation plays a role in childhood ALL and have defined a genome-scale DNA methylation 
profile associated with the ETV6-RUNX1 subtype of pediatric ALL. Archival bone marrow smears from 19 children 
collected at diagnosis and remission were used to derive a disease specific DNA methylation profile. the gene signature 
was confirmed in an independent cohort of 86 patients. A further 163 patients were analyzed for DNA methylation of 
a three gene signature. We found that the DNA methylation signature at diagnosis was unique from remission. fifteen 
loci were sufficient to discriminate leukemia from disease-free samples and purified CD34+ cells. DNA methylation of 
these loci was recurrent irrespective of cytogenetic subtyp  of pre-B cell ALL. We show that recurrent aberrant genomic 
methylation is a common feature of pre-B ALL, suggesting a shared pathway for disease development. By revealing new 
DNA methylation markers associated with disease, this study has identified putative targets for development of novel 
epigenetic-based therapies.
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Results
Our initial experiments using SEQUENOM EpiTYPER con-
firmed the stability of DNA methylation between matched cryo-
preserved bone marrow and archived bone marrow taken from 
the same individual (Pearson’s correlation coefficient = 0.97, 
Fig. S1). As a first step toward fully examining the degree of epi-
genetic disruption associated with pediatric ALL, we measured 
DNA methylation at 27,578 CpG sites on DNA extracted from 
microscope slide archived primary bone marrow aspirates from 
ETV6-RUNX1 positive pediatric ALL cases. To identify disease-
specific changes in DNA methylation, we directly compared sam-
ples taken at diagnosis, matching 28-day post induction (remission 
sample) and long-term follow-up archived primary bone marrow 
aspirates taken up to a year post induction (follow up).
Genome-scale DNA methylation was profiled in 19 children 
diagnosed with ETV6-RUNX1 pre-B ALL who are currently in 
remission (11 male, 8 female), of which 16 children had match-
ing leukemic and remission bone marrow samples for comparison 
(Table 1). Bone marrow samples from unrelated healthy donors 
were analyzed as controls including CD34+ bone marrow-
derived cells and CD34+, CD19+, CD33+ and CD34-/CD19-/
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performance of these three methods using 3-fold cross-valida-
tion, iterated ten times revealed that DNA methylation of at least 
15 CpG sites could discriminate leukemic from disease-free bone 
marrow samples with 100% accuracy (Fig. S3).
To increase our confidence in identifying a disease-specific 
DNA methylation profile and to select potential candidate mark-
ers for validation, we identified 115 (57.5%) common probes 
ranked within the top 200 probes by each method of feature 
selection (Fig. S4 and Table S1). We found a robust and dis-
tinct DNA methylation pattern that discriminates leukemia from 
matching remission bone marrow and healthy controls (Fig. 2; 
Table S2). The leukemic DNA methylation pattern was distinct 
from CD34+, CD19+, CD33+ and CD34/CD19/CD33 negative 
cell fractions, which were more similar to primary remission mar-
row supporting the existence of a leukemia-specific DNA meth-
ylation profile (Fig. 2). The majority of discriminating probes 
(112/115, 97%) were hypermethylated in leukemic bone marrow 
(Fig. 3). As the Infinium methylation array platform focuses on 
gene promoters, the observed hypermethylation in leukemic bone 
marrow suggests the potential for recurrent aberrant expression 
of associated genes.
Ingenuity Pathway Analysis (Ingenuity® Systems, www.
ingenuity.com) of the associated genes revealed enhanced rep-
resentation of genes involved with developmental processes, cel-
lular differentiation and cancer. This was supported by DAVID 
analysis7 to reveal a range of transcription factors implicated 
CD33- Fluorescence Activated Cell Sorted (FACS) fractions 
from unrelated healthy donor children. Leukemic (CCRF-CEM, 
REH and K562) and solid cancer cell lines [MCF-7 (breast), 
SW48 (colon)] were also analyzed for genome scale DNA meth-
ylation for comparative purposes (Fig. 1).
DNA methylation probes with p value detection of less than 
0.05 across all samples (14,876 probes) were analyzed for initial 
exploratory analysis. We observed a higher average methylation 
level (β-value) across all probes analyzed in the ETV6-RUNX1 
leukemic bone marrow samples [0.29 ± 0.04 (SD)] when com-
pared with remission (0.22 ± 0.01, paired Student’s t-test with 
Bonferroni Correction for multiple testing p = 0.049) and dis-
ease-free control marrow samples (0.24 ± 0.01), indicative of 
global gene promoter hypermethylation of the leukemic genome 
(Fig. S2).
Unsupervised hierarchical clustering of the 14,876 probes 
clearly delineated primary leukemia bone marrow from remission 
bone marrow and non-leukemic control samples (Fig. 1).
A DNA methylation signature specific to ETV6-RUNX1 leu-
kemic bone marrow was then defined using three methods of 
supervised machine learning analysis for classifier and feature 
selection. These methods were applied to the entire data set 
(27,578 probes) to identify a core set of ranked DNA methylation 
probes that reliably discriminate between leukemic and matched 
remission bone marrow samples (details of the methods used are 
outlined in the Supplemental Mataterial). The classification 
Table 1. ETV6-RUNX1 positive case and clinical annotations used in this study for genome-scale DNA methylation analyses
ID Age at Dx (y) Sex Karyotype
Samples analyzed by Illumina Infinium
Leukemia Remission Follow Up
235 5.13 f 46,XX,del(12)(p13)[3]/46,XX[14] Yes Yes Yes
088 9.32 M 46,XY,i(21)(q10)[15]/46,XY[1] No Yes Yes
102 2.97 M 47,XY,+21c Yes No No
084 7.37 M 46,XY No Yes Yes
089 5.37 M 46,XY Yes No No
094 7.24 M 46,XY,del(7)(q32),-11,+r[3]/46,XY[7] Yes No No
114 6.96 f 46,XX No Yes Yes
123 5.99 f 46,XX Yes No No
127 4.76 f 46,XX,del(11)(q23)[2]/45,X,-X,del(11)(q23),inc[5]/46,XX [5], Yes Yes No
133 2.37 M 46,XY, Yes No Yes
143 13.05 f
45,X,-X,del(6)(q21),add(12)(p13),-13,+16[3]/46,idem,+21[2]
/46,XX[7]
Yes No Yes
175 2.81 M 46, XY Yes Yes No
216 4.21 M
46,XY nuc ish(tELx2),(AML1x3),(tEL con AML1x1)[185/199]/
(MLLx1) [39/198]
Yes Yes Yes
119 3.17 f 46,XX Yes No No
199 5.57 M NA Yes No No
344 2.57 f 47,X,-X,?add(9)(q34),+10,add(12)(p1?3),+mar[6]/46,XX[9] Yes Yes Yes
177 9.11 M 46,XY Yes No No
365 2.28 M 46,XY Yes Yes No
144 6.96 f 46,XX Yes No No
NA, not available. ETV6-RUNX1 fusion detection was performed by standard molecular testing.
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with genome-wide gene expression analysis. By comparing with 
a publically available data set from a pediatric B cell ALL study 
of gene expression,15 we investigated the gene expression status of 
the top 200 differentially methylated genes we identified using 
RFE-SVM. We were able to compare our DNA methylation 
results with associated gene expression on 99 genes. We found 12 
unmethylated leukemic genes were expressed in ETV6-RUNX1 
leukemia cases while most of the remaining genes were meth-
ylated and silenced. In addition to TCF3, we found POU2AF1 
and RAG1 were unmethylated and expressed in ETV6-RUNX1 
leukemia cases (Table S4). RAG1 is an essential factor for Ig rear-
rangement and B cell differentiation.16 POU2AF1 along with 
BTG4 have been implicated in chronic lymphocytic leukemia 
previously17 and expression of POU2AF1 has been found to have 
prognostic significance in myeloma18 and lymphoma.19 However, 
their role in pediatric B cell ALL remains to be characterized. 
The gene expression profile of these 12 genes remained after 
extending to all B cell leukemia subtypes that were analyzed by 
Yeoh et al. (Fig. S5).
Our feature selection analysis demonstrated that at least 15 
CpG methylation features are required to distinguish leuke-
mia from remission samples (Fig. S3A). For replication of our 
microarray results, we selected 15 of the 115 common probes for 
SEQUENOM EpiTYPER analysis on 85 childhood B cell leu-
kemia cases with matching leukemic and remission bone mar-
row aspirates (Fig. 4). The selected cases represented a range of 
in cell fate commitment, gene regulation and DNA binding 
(Table S3) where DNA methylation may have impaired gene 
function through transcription silencing or activation. We iden-
tified hypermethylation of CpG sites associated with genes pre-
viously implicated in cancer and leukemia including MYOD1,8 
PTPRZ1, PPARG9 and SFRP1.10 We also found hypermethyl-
ation of associated genes not previously implicated in cancer or 
leukemia. These include promoter methylation of genes encoding 
FOXE3, a forkhead transcription factor required for eye develop-
ment (reviewed in ref. 11), f-box protein FBXO39 and signaling 
receptor PKDREJ. Genes important in hematopoiesis were also 
identified, including aberrant methylation of TCF3,12 EGR4 13 
and BTG4 in the leukemic samples. TCF3 is an important tran-
scription factor for B cell differentiation and is the transloca-
tion gene partner in t(1;19) ALL.1 With the exception of TCF3, 
which was hypomethylated in leukemic samples, we did not find 
coordinate DNA methylation of genes such as PAX5 or IKZF1.4 
However, TLX3 (HOX11L2), a critical gene in childhood T-cell 
leukemia that is activated14 and frequently mutated,1 was com-
monly hypermethylated in our B cell leukemic samples (Tables 
S1 and S2). The recurrent dysregulation of DNA methylation we 
observe here suggests that common gene pathways are affected 
by DNA methylation that could contribute the required second 
oncogenic hit for leukemogenesis.
As the samples we used here were more akin to formalin fixed 
paraffin embedded (FFPE) material, they were not compatible 
Figure 1. Unsupervised clustering of infinium β-values of 14,876 probes (p-detection value < 0.05) accurately delineates disease free tissue from 
leukemia.
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types, our comparisons with FACS purified CD34+, CD33+ and 
CD19+ cells from healthy bone marrow, representing undif-
ferentiated hematopoietic cells, myeloid cells and differenti-
ated B cells respectively, show remarkable similarity in DNA 
methylation profile to the remission samples analyzed. These 
disease-specific DNA methylation markers correlate with asso-
ciated gene expression. We found aberrant methylation of criti-
cal genes involved in B cell development and hematopoiesis were 
concordant with aberrant gene expression from an independent 
study.15 This supports a regulatory role of aberrant DNA meth-
ylation on gene expression in pediatric B cell ALL. Furthermore, 
the DNA methylation signature we have identified by genome-
scale DNA methylation analysis of ETV6-RUNX1 B cell ALL 
exists in the majority of all other subtypes of B cell ALL we 
analyzed. Our observation suggests that we have identified a 
pan B cell ALL DNA methylation signature. The expression 
status of genes associated with this signature correlated with the 
DNA methylation state, which also applied to other B cell ALL 
subtypes. Most of these genes have not been previously impli-
cated in pediatric B cell ALL making these biomarkers an area 
of interest for future studies.
Our DNA methylation profile will enable the distinction to 
be made between leukemic and non-leukemic samples based on 
pediatric ALL subtypes categorized according to cytogenetic 
karyotyping that include ETV6-RUNX1, hyperdiploidy, normal 
karyotype and other rare subtypes (Fig. 4). Strikingly, DNA 
hypermethylation of these 15 probes were able to clearly dis-
criminate leukemic from remission bone marrow regardless of 
ALL subtype in 77/85 (91%) cases, demonstrating that recurrent 
DNA hypermethylation is a common feature of pediatric B cell 
ALL (Fig. 4). The remaining 8/85 (9%) cases that were misclas-
sified comprised of cases with abnormal chromosome number 
(hypodiploidy). When a further 163 pediatric B cell ALL cases 
were analyzed at the C1orf76, FBXO39 and MYOD1 genes, DNA 
hypermethylation was still observed (151/163, 93%) in leukemic 
bone marrow samples (Fig. S6) confirming the existence of a 
pan-DNA methylation signature in pediatric B cell ALL.
Discussion
We have identified a set of recurrent DNA methylation changes 
associated with pre-B cell ALL regardless of cytogenetic subtype 
when compared with matching remission bone marrow samples. 
Although these methylation differences may be attributed to 
differences in cellular composition due to remission bone mar-
row samples consisting of heterogeneous and differentiated cell 
Figure 2. Unsupervised clustering heatmap plot of the DNA methylation β-values from the illumina infinium HumanMethylation27 BeadArray of 115 
ALL-specific probes identified using three supervised learning methods (x-axis) (Table S2). three distinct clusters comprising the leukemia, remission/
non-leukemic and the cell lines are apparent (y-axis).
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could potentially be targeted by therapeutic reagents designed 
to demethylate DNA, some of which are currently being used 
in adult leukemia and therefore presents a novel avenue for the 
treatment, diagnosis and monitoring of pediatric pre-B ALL in 
the future.
Materials and Methods
Patient samples. This study was reviewed and approved by the 
Royal Children’s Hospital Human Research Ethics Committee 
(HREC27138). Archived bone marrow aspirate microscope 
slides were used to obtain genomic DNA. After incubation in 
xylene to remove the coverslip and resin, the smear was scraped 
off the microscope slide in the presence of lysis buffer and pro-
teinase K. Standard phenol-chloroform extraction and ethanol 
precipitation was performed to isolate genomic DNA. Genomic 
DNA from flash frozen bone marrow samples collected from 
healthy children and cells isolated using Fluorescence Activated 
Cell Sorting (FACS) with antibodies against CD34, CD19 and 
CD33 were also extracted using standard phenol-chloroform 
extraction.
Illumina infinium humanmethylation27 bead array analy-
sis. Genomic DNA from the selected samples were hybridized 
an “epigenotype” that could potentially overcome some of the 
technical limitations associated with current minimal residual 
disease detection methods.20 For example, PCR-based DNA 
rearrangement assays currently require a laborious patient-by-
patient workup, while fluorescence activated cell sorting (FACS) 
methods are susceptible to false positive and false negative detec-
tion. A sensitive, multilocus DNA methylation assay specific to 
all subtypes of B cell leukemia would have enhanced specificity 
and alleviate the need for patient specific workup.
Many of these aberrantly methylated CpG sites may be 
important contributors to leukemogenesis either through silenc-
ing or activation of associated genes. The genes identified in this 
study are distinct from other genome-scale DNA methylation 
analyses of cancer21-23 and have not been described in pediatric 
B cell ALL previously. Our study opens up new opportunities 
for exploring linkages between gene dysregulation, DNA meth-
ylation and pediatric pre-B ALL. Importantly it suggests that 
despite pediatric ALL cases having disparate primary cytoge-
netic lesions, most share recurrent DNA methylation changes 
within common pathways likely to be involved in pathogenesis, 
raising the possibility that all forms of this disease may have a 
common secondary trigger mediated by DNA methylation. As 
DNA methylation is a reversible modification, this signature 
Figure 3. Box and whisker plot showing distribution of DNA methylation β-values of the top 115 features that discriminate sample type. Average 
β-values from all leukemic and remission samples analyses for each feature was calculated. the median β-value of these features was significantly 
higher in the leukemic bone marrow samples (avgLeuk) compared with the matched remission (avgrem), CD34+, CD19+ and CD34/CD19 negative 
(neg_frac) cell samples highlighting the specific DNA hypermethylation signature of leukemia.
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SEQUENOM EpiTYPER analysis of locus specific DNA 
methylation. Genomic DNA was subjected to bisulfite conver-
sion using MethylEasy Xceed Bisulfite Modification Kit (Human 
Genetic Signatures). Converted DNA was eluted with sufficient 
volume of elution buffer to give a final sample concentration of 
20 ng/μL.
PCR amplification of 10 ng of bisulfite converted genomic 
DNA was performed using gene specific primers containing 
the necessary tags for SEQUENOM EpiTYPER (Table S5). 
Fast Start PCR master mix (Roche Applied Sciences) was used 
according to manufacturer’s instructions to generate amplicons 
for downstream EpiTYPER chemistry. Typical PCR cycling 
by the Australian Genome Research Facility (AGRF) and ana-
lyzed according to manufacturer’s protocol. Raw β-values and 
probe intensities were extracted using Illumina Genome Studio 
Software (data has been deposited into GEO Database with 
accession number GSE 29189).
We have used three different variants of supervised learning 
analysis to detect the set of features (probes) critical for discrimi-
nation between leukemia and remission bone marrow samples. 
These were centroid feature selection, linear model for micro-
array analysis (LIMMA) and recursive feature elimination sup-
port vector machine (RFE-SVM). Further details are found in 
Supplemental Methods.
Figure 4. Heatmap plot of SEQUENoM EpitYpEr DNA methylation results generated from 85 cases of B cell ALL with matching leukemic and remis-
sion bone marrow samples, controls (DoNor) and cancer cell line (rEH). DNA methylation data for a total of 103 CpG sites encompassing 15 probes we 
selected by infinium analysis are shown here (x-axis). DNA hypermethylation of 77/85 (91%) leukemic bone marrow samples was observed regardless 
of ALL subtype suggesting the existence of a DNA methylation signature associated with leukemia.
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conditions performed were: denaturation at 95°C for 10 min fol-
lowed by 5 cycles of denaturation at 95°C for 10 sec, annealing at 
56°C for 20 sec, extension at 72°C for two minutes and 40 cycles 
of denaturation at 95°C for 10 sec, annealing at 56°C for 20 sec 
and extension at 72°C for 1.5 min. Successful amplicons were 
then subjected to SEQUENOM EpiTYPER chemistry consist-
ing of shrimp alkaline phosphatase treatment, RNA transcription 
and RNase cleavage prior to matrix-assisted laser desorption/ion-
ization time of flight (MALDI-TOF) analysis as outlined in the 
manufacturer’s instructions. Mass spectra were processed using 
the EpiTYPER viewer software v1.0.5 (SEQUENOM Inc.) and 
cleaned using an in-house R-script to remove poor quality CpG 
units and samples. Heatmaps of SEQUENOM data were then 
drawn using heatmap.2 of the gplots library in R (www.r-project.
org).
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgments
The SEQUENOM Platform Facility at Murdoch Childrens 
Research Institute managed and maintained by Benjamin Ong. 
References
1. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, 
risk stratification and therapy of pediatric acute leu-
kemias: an update. J Clin Oncol 2011; 29:551-
65; PMID:21220611; http://dx.doi.org/10.1200/
JCO.2010.30.7405.
2. Gale KB, Ford AM, Repp R, Borkhardt A, Keller 
C, Eden OB, et al. Backtracking leukemia to birth: 
identification of clonotypic gene fusion sequences 
in neonatal blood spots. Proc Natl Acad Sci USA 
1997; 94:13950-4; PMID:9391133; http://dx.doi.
org/10.1073/pnas.94.25.13950.
3. Bernardin F, Yang Y, Cleaves R, Zahurak M, Cheng L, 
Civin CI, et al. TEL-AML1, expressed from t(12;21) 
in human acute lymphocytic leukemia, induces acute 
leukemia in mice. Cancer Res 2002; 62:3904-8; 
PMID:12124316.
4. Mullighan CG, Goorha S, Radtke I, Miller CB, 
Coustan-Smith E, Dalton JD, et al. Genome-wide anal-
ysis of genetic alterations in acute lymphoblastic leu-
kaemia. Nature 2007; 446:758-64; PMID:17344859; 
http://dx.doi.org/10.1038/nature05690.
5. Gutiérrez MI, Siraj AK, Ibrahim MM, Hussain A, 
Bhatia K. Childhood and adult ALL: differences in 
epigenetic lesions associated with cell cycle genes. Am 
J Hematol 2005; 80:158-60; PMID:16184585; http://
dx.doi.org/10.1002/ajh.20458.
6. Chatterton Z, Morenos L, Saffery R, Craig JM, 
Ashley D, Wong NC. DNA methylation and miRNA 
expression profiling in childhood B-cell acute lym-
phoblastic leukemia. Epigenomics 2010; 2:697-
708; PMID:22122053; http://dx.doi.org/10.2217/
epi.10.39.
7. Huang W, Sherman BT, Lempicki RA. Systematic and 
integrative analysis of large gene lists using DAVID 
bioinformatics resources. Nat Protoc 2009; 4:44-
57; PMID:19131956; http://dx.doi.org/10.1038/
nprot.2008.211.
8. Martin-Subero JI, Ammerpohl O, Bibikova M, 
Wickham-Garcia E, Agirre X, Alvarez S, et al. A com-
prehensive microarray-based DNA methylation study 
of 367 hematological neoplasms. PLoS One 2009; 
4:6986; PMID:19750229; http://dx.doi.org/10.1371/
journal.pone.0006986.
9. Ogino S, Shima K, Baba Y, Nosho K, Irahara N, 
Kure S, et al. Colorectal cancer expression of per-
oxisome proliferator-activated receptor gamma 
(PPARG, PPARgamma) is associated with good 
prognosis. Gastroenterology 2009; 136:1242-50; 
PMID:19186181; http://dx.doi.org/10.1053/j.gas-
tro.2008.12.048.
10. Sun J, Chen Z, Zhu T, Yu J, Ma K, Zhang H, et al. 
Hypermethylated SFRP1, but none of other nine genes 
“informative” for western countries, is valuable for 
bladder cancer detection in Mainland China. J Cancer 
Res Clin Oncol 2009; 135:1717-27; PMID:19565266; 
http://dx.doi.org/10.1007/s00432-009-0619-z.
11. Katoh M, Katoh M. Human FOX gene family (Review). 
Int J Oncol 2004; 25:1495-500; PMID:15492844.
12. Lin YC, Jhunjhunwala S, Benner C, Heinz S, Welinder 
E, Mansson R, et al. A global network of transcrip-
tion factors, involving E2A, EBF1 and Foxo1, that 
orchestrates B cell fate. Nat Immunol 2010; 11:635-43; 
PMID:20543837; http://dx.doi.org/10.1038/ni.1891.
13. Scholz C, Nimmrich I, Burger M, Becker E, Dörken B, 
Ludwig WD, et al. Distinction of acute lymphoblastic 
leukemia from acute myeloid leukemia through micro-
array-based DNA methylation analysis. Ann Hematol 
2005; 84:236-44; PMID:15538567; http://dx.doi.
org/10.1007/s00277-004-0969-1.
14. Ballerini P, Landman-Parker J, Cayuela JM, Asnafi V, 
Labopin M, Gandemer V, et al. Impact of genotype 
on survival of children with T-cell acute lymphoblastic 
leukemia treated according to the French protocol 
FRALLE-93: the effect of TLX3/HOX11L2 gene 
expression on outcome. Haematologica 2008; 93:1658-
65; PMID:18835836; http://dx.doi.org/10.3324/hae-
matol.13291.
15. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel 
D, Mahfouz R, et al. Classification, subtype discovery 
and prediction of outcome in pediatric acute lympho-
blastic leukemia by gene expression profiling. Cancer 
Cell 2002; 1:133-43; PMID:12086872; http://dx.doi.
org/10.1016/S1535-6108(02)00032-6.
16. van Zelm MC, van der Burg M, de Ridder D, 
Barendregt BH, de Haas EF, Reinders MJ, et al. 
Ig gene rearrangement steps are initiated in early 
human precursor B cell subsets and correlate with spe-
cific transcription factor expression. J Immunol 2005; 
175:5912-22; PMID:16237084.
17. Auer RL, Starczynski J, McElwaine S, Bertoni F, 
Newland AC, Fegan CD, et al. Identification of 
a potential role for POU2AF1 and BTG4 in the 
deletion of 11q23 in chronic lymphocytic leuke-
mia. Genes Chromosomes Cancer 2005; 43:1-10; 
PMID:15672409; http://dx.doi.org/10.1002/
gcc.20159.
18. Toman I, Loree J, Klimowicz AC, Bahlis N, Lai R, 
Belch A, et al. Expression and prognostic significance of 
Oct2 and Bob1 in multiple myeloma: implications for 
targeted therapeutics. Leuk Lymphoma 2011; 52:659-
67; PMID:21438833; http://dx.doi.org/10.3109/1042
8194.2010.548535.
19. Advani AS, Lim K, Gibson S, Shadman M, Jin T, 
Copelan E, et al. OCT-2 expression and OCT-2/
BOB.1 co-expression predict prognosis in patients 
with newly diagnosed acute myeloid leukemia. Leuk 
Lymphoma 2010; 51:606-12; PMID:20141429; 
http://dx.doi.org/10.3109/10428191003592735.
20. Cazzaniga G, Valsecchi MG, Gaipa G, Conter V, 
Biondi A. Defining the correct role of minimal resid-
ual disease tests in the management of acute lympho-
blastic leukaemia. Br J Haematol 2011; 155:45-52; 
PMID:21812769; http://dx.doi.org/10.1111/j.1365-
2141.2011.08795.x.
21. Fackler MJ, Umbricht CB, Williams D, Argani P, 
Cruz LA, Merino VF, et al. Genome-wide methylation 
analysis identifies genes specific to breast cancer hor-
mone receptor status and risk of recurrence. Cancer Res 
2011; 71:6195-207; PMID:21825015; http://dx.doi.
org/10.1158/0008-5472.CAN-11-1630.
22. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun 
HM, Van Den Berg D, et al. Genome-scale analysis 
of aberrant DNA methylation in colorectal cancer. 
Genome Res 2012; 22:271-82; PMID:21659424; 
http://dx.doi.org/10.1101/gr.117523.110.
23. Fang F, Turcan S, Rimner A, Kaufman A, Giri D, 
Morris LG, et al. Breast cancer methylomes establish 
an epigenomic foundation for metastasis. Sci Transl 
Med 2011; 3:75; PMID:21430268; http://dx.doi.
org/10.1126/scitranslmed.3001875.
